Hot off the press in JCO Oncology Practice ! It was a pleasure to write this editorial with the brilliant Dr. Nina Niu Sanford on how to manage FCOI in oncology. We make 4 specific recommendations, which we believe can move the needle in the right direction. It’s free to read:

Despite manufacturing costs ~67 000 €, academic TIL therapy for patients with #melanoma is both cost-saving and cost-effective in 🇩🇰 and 🇱🇺 Publicly-funded #celltherapy can be sustainable!

All you need to know about Cancer Biomarkers. Access via cell.com/cell/fulltext/…

Excited to see our phase 2 multicenter study of Tumor-Infiltrating Lymphocyte in Advanced #LungCancer Resistant to Immunotherapy in Cancer Discovery. #TIL #Celltherapy aacrjournals.org/cancerdiscover…

Ph II trial of TIL therapy (Lifileucel) in Adv NSCLC post IO+/-chemo: - Pre-conditioning chemo (cyclophos/fludara)➡️TIL➡️IL2 - ORR 21.4% (6/28) - In 60% cases, TIL from lung mets - 2 tx-related deaths ⁦⁦Adam J. Schoenfeld⁩ ⁦OncoAlert⁩ #LCSM aacrjournals.org/cancerdiscover…

Privilege to work with JonssonMelanomaLab 👉Molecular Resistance to anti-PD1 or anti-CTLA-4 in #melanoma

nature highlights new research and clinical tools from University of Pittsburgh, UPMC Enterprises, and UPMC Hillman Cancer Center to treat metastatic uveal melanoma with t-cell therapy. nature.com/articles/s4146…

Lauss et al. analyzed the tumor cell-intrinsic and immune TME features of human melanoma specimens collected after progression on ICB, and highlighted that anti-CTLA-4 and anti-PD-1 resistance [...] bit.ly/3UAl2rK  CCIT-DK: National Center for Cancer Immune Therapy  Marco Donia  JonssonMelanomaLab

Just out in JAMA Oncology Marco Donia, Herlev Hospital Copenhagen and I explain why IPI-NIVO and RELA-NIVO do NOT WORK if your PDL1 is >1% This is another FDA Oncology error jamanetwork.com/journals/jamao… VKPrasadLab 3 piece of evidence 🧵

Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy. ja.ma/3WKIrZ0

It will be my pleasure to coordinate this workshop with a talented group of yEFIS fellows!

🟣 Lessons from melanoma and growing evidence in NSCLC for TIL therapy and microbiota modulation by Marco Donia 🧐 Up to 40% response rate in naive NSCLC pts 🧐 Pt selection and global access may be an issue 🦠 is biomarker and potentially modulated SEOM Grupo Español de Cáncer de Pulmón

Excited to be a part of the Swiss Oncology Summer School, brainchild of Curioni_Oncology_MD A dynamic program aimed at training the next generation of clinician scientists in oncology Looking forward to joining G Curigliano MD PhD Ben Westphalen Marco Donia Solange Peters Christian Rolfo et al

Thank you all !!! Amazing faculty !!! 🙌 Solange Peters Marco Donia Jarushka Naidoo George Coukos Berend Snijder M. Bentires-Alj Ben Westphalen G Curigliano MD PhD lisaderosa Faculty of Science and Medicine Fribourg ETH Zurich We did it! You have inspired these incredible students: bridging science in oncology

#Melanoma at #ESMO24 (Proffered Paper Session) My summary at 👇 linkedin.com/posts/marcodon… ESMO - Eur. Oncology

Long-Term Survival in a growing number of cancers at #ESMO24 👉 Press release at esmo.org/newsroom/press… (commented by Curioni_Oncology_MD and me) 1⃣ High-risk, Triple Negative #BreastCancer 2⃣Muscle-invasive #bladdercancer 3⃣Metastatic #Melanoma 🙏 Thanks to ESMO - Eur. Oncology